티움바이오

321550KOSDAQ자연과학 및 공학 연구개발업

57.0 / 100

Reference Date: 2026-04-13

Financial Score13.5 / 40

News Sentiment20.5 / 25

Momentum13.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, PBR raises overvaluation concerns. Surged 30.9% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Tium Bio is a biopharmaceutical company founded by a team that successfully developed and licensed the FDA-approved hemophilia treatment Afstyla, focusing on R&D for rare and intractable diseases. The company develops both small-molecule synthetic drugs and biopharmaceuticals, with several drug candidates in clinical trials, including NCE401 and NBP604. In 2024, Tium Bio acquired Petraon Care Lab, a natural cosmetics OEM/ODM firm, and operates Protiom Science, a CDAO company providing specialized biopharmaceutical process development services.

Number of Employees

67people

Average Salary

57.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 120.074.0Point

PBR

7.71Industry Average 3.820.0Point

2.0x industry avg (risky)

ROE

-42.45Industry Average -32.113.5Point

In line with industry avg

Debt Ratio

39.36Industry Average 7.520.0Point

5.2x industry avg (risky)

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲59.8% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲23.2% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -36.7% (declining, 3yr)

Detailed News Sentiment

5 totalPositive 4Neutral 0Negative 0Average Sentiment Score 90

Positive
티움바이오, 임상 2a상 면역항암제 중간결과 美 발표
티움바이오의 면역항암제 후보물질 '토스포서팁(TU2218)' 임상 2a상 중간결과가 2026 미국임상종양학회(ASCO 2026)에서 초록으로 채택되어 글로벌 기회 모색에 나선다.
Positive
티움바이오, 면역항암제 ‘토스포서팁(TU2218)’ 임상 성과 ASC...
티움바이오의 면역항암제 '토스포서팁(TU2218)' 임상 데이터가 2026 미국임상종양학회(ASCO2026) 초록으로 채택되어 임상 성과를 발표할 예정이다.
Positive
‘두경부암 판 흔든 ORR 70%’…티움바이오 TU2218, 글로벌 딜...
티움바이오의 경구용 면역항암제 후보물질 'TU2218'이 두경부암 임상에서 객관적 반응률(ORR) 70%를 넘는 성과를 기록하며 글로벌 기술수출 기대감을 키우고 있다.

Detailed Momentum

52-week position6.0Point

52w upper range (69%)

Current 10,010Won52-week high 12,90052-week low 3,270

1-month return6.0Point

1m +30.85% (strong rise)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0

Neutral기업설명회(IR)개최2026-04-03
Neutral기업설명회(IR)개최2026-04-03
Neutral정기주주총회결과2026-03-26
Neutral사업보고서 (2025.12)2026-03-18
Neutral감사보고서제출2026-03-18